We are analyzing https://link.springer.com/article/10.1007/bf00694753.

Title:
Aberrant function of the Ras signal transduction pathway in human breast cancer | Breast Cancer Research and Treatment
Description:
Althoughras mutations are infrequent (approximately 5%) in breast cancers, there is considerable evidence that suggests that the pathways which Ras services may still be deregulated in breast cancer cells. The recent identification of many of the components of the Ras signal transduction pathway has defined a network of proto-oncogene proteins controlling diverse signaling events that regulate cell growth and differentiation. Consequently, mutations that perturb the function of any one component of this signal pathway may trigger the same oncogenic events as mutation ofras itself. Moreover, several Ras-related proteins have recently been demonstrated to possess the ability to trigger malignant transformation via signaling pathways shared with Ras proteins. Thus, it is possible that the aberrant function of Ras-related proteins may contribute to breast cancer development. Consequently, it is important not to dismiss the Ras pathway in the development of breast cancer merely because of the infrequent detection of mutations inras itself, but rather to consider the influence of aberrations upstream or downstream of Ras and of certain Ras-related proteins in the development of breast cancer. Finally, the critical importance of components upstream and downstream of Ras provides additional targets for rational drug design approaches to block the aberrant function of Ras signaling in human tumors.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Telecommunications

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,625,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't see how the site brings in money.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

google, scholar, cell, ras, cancer, protein, breast, biol, proteins, human, nature, signaling, sci, usa, signal, cells, transformation, natl, science, kinase, function, proc, acad, transduction, oncogene, mol, article, pathway, clark, growth, activation, raf, gene, oncogenes, mccormick, domain, domains, pathways, res, cox, aberrant, rasrelated, malignant, pras, activity, privacy, cookies, content, research, oncogenic,

Topics {✒️}

mmtv/v-ha-ras ras-specific exchange factor extra-cellular-signal regulated kinases mitogen-activated protein kinase gtp-binding protein ran/tc4 c-ha-ras oncogene r-ras induces malignant ras signalling pathway inhibit ras-dependent growth her2/neu proto-oncogene carboxyl-terminal cysteine residues small gtp-binding proteins month download article/chapter map kinase kinase bcr-abl-induced oncogenesis serine/threonine kinase raf mmtv/c-myc genes ras p21-dependent inhibition amino-terminal regulatory domain theets-2 dna-binding domain receptor tyrosine kinases c-terminal sh2 region r-ras interacts mutation ofras induced nih/3t3 cells malignant tumor growth signaling pathways shared ras-related proteins diverse cell functions diverse signaling proteins ras-gap-mediated signaling gtp-binding proteins human breast cancer privacy choices/manage cookies raf-1 protein kinase amino-terminal region nuclearras-related polypeptide oncogenic ras signaling regulate cell growth cytoplasmic signaling proteins ras-related gtpases protein functionally related gap-related domain breast cancer cells her2/neu oncogene mutant ras proteins proteins regulating ras independent molecular pathways selective cleavage reaction geranylgeranyl-modified proteins

Questions {❓}

Cox AD, Der CJ: Protein prenylation: more than just glue?
Hall A:ras and GAP — who's controlling whom?
Khosravi-Far R, Cox AD, Kato K, Der CJ: Protein prenylation: key to ras function and cancer intervention?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Aberrant function of the Ras signal transduction pathway in human breast cancer
         description:Althoughras mutations are infrequent (approximately 5%) in breast cancers, there is considerable evidence that suggests that the pathways which Ras services may still be deregulated in breast cancer cells. The recent identification of many of the components of the Ras signal transduction pathway has defined a network of proto-oncogene proteins controlling diverse signaling events that regulate cell growth and differentiation. Consequently, mutations that perturb the function of any one component of this signal pathway may trigger the same oncogenic events as mutation ofras itself. Moreover, several Ras-related proteins have recently been demonstrated to possess the ability to trigger malignant transformation via signaling pathways shared with Ras proteins. Thus, it is possible that the aberrant function of Ras-related proteins may contribute to breast cancer development. Consequently, it is important not to dismiss the Ras pathway in the development of breast cancer merely because of the infrequent detection of mutations inras itself, but rather to consider the influence of aberrations upstream or downstream of Ras and of certain Ras-related proteins in the development of breast cancer. Finally, the critical importance of components upstream and downstream of Ras provides additional targets for rational drug design approaches to block the aberrant function of Ras signaling in human tumors.
         datePublished:
         dateModified:
         pageStart:133
         pageEnd:144
         sameAs:https://doi.org/10.1007/BF00694753
         keywords:
            oncogenes
            ras oncogene
            Ras-related proteins
            rational drug design
            signal transduction pathways
            Oncology
         image:
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:35
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Kluwer Academic Publishers
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Geoffrey J. Clark
               affiliation:
                     name:University of North Carolina at Chapel Hill
                     address:
                        name:Department of Pharmacology, and the Lineberger Comprehensive Cancer Center, CB #7365 FLOB, University of North Carolina at Chapel Hill, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Channing J. Der
               affiliation:
                     name:University of North Carolina at Chapel Hill
                     address:
                        name:Department of Pharmacology, and the Lineberger Comprehensive Cancer Center, CB #7365 FLOB, University of North Carolina at Chapel Hill, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Aberrant function of the Ras signal transduction pathway in human breast cancer
      description:Althoughras mutations are infrequent (approximately 5%) in breast cancers, there is considerable evidence that suggests that the pathways which Ras services may still be deregulated in breast cancer cells. The recent identification of many of the components of the Ras signal transduction pathway has defined a network of proto-oncogene proteins controlling diverse signaling events that regulate cell growth and differentiation. Consequently, mutations that perturb the function of any one component of this signal pathway may trigger the same oncogenic events as mutation ofras itself. Moreover, several Ras-related proteins have recently been demonstrated to possess the ability to trigger malignant transformation via signaling pathways shared with Ras proteins. Thus, it is possible that the aberrant function of Ras-related proteins may contribute to breast cancer development. Consequently, it is important not to dismiss the Ras pathway in the development of breast cancer merely because of the infrequent detection of mutations inras itself, but rather to consider the influence of aberrations upstream or downstream of Ras and of certain Ras-related proteins in the development of breast cancer. Finally, the critical importance of components upstream and downstream of Ras provides additional targets for rational drug design approaches to block the aberrant function of Ras signaling in human tumors.
      datePublished:
      dateModified:
      pageStart:133
      pageEnd:144
      sameAs:https://doi.org/10.1007/BF00694753
      keywords:
         oncogenes
         ras oncogene
         Ras-related proteins
         rational drug design
         signal transduction pathways
         Oncology
      image:
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:35
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Kluwer Academic Publishers
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Geoffrey J. Clark
            affiliation:
                  name:University of North Carolina at Chapel Hill
                  address:
                     name:Department of Pharmacology, and the Lineberger Comprehensive Cancer Center, CB #7365 FLOB, University of North Carolina at Chapel Hill, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Channing J. Der
            affiliation:
                  name:University of North Carolina at Chapel Hill
                  address:
                     name:Department of Pharmacology, and the Lineberger Comprehensive Cancer Center, CB #7365 FLOB, University of North Carolina at Chapel Hill, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:35
Organization:
      name:Kluwer Academic Publishers
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of North Carolina at Chapel Hill
      address:
         name:Department of Pharmacology, and the Lineberger Comprehensive Cancer Center, CB #7365 FLOB, University of North Carolina at Chapel Hill, USA
         type:PostalAddress
      name:University of North Carolina at Chapel Hill
      address:
         name:Department of Pharmacology, and the Lineberger Comprehensive Cancer Center, CB #7365 FLOB, University of North Carolina at Chapel Hill, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Geoffrey J. Clark
      affiliation:
            name:University of North Carolina at Chapel Hill
            address:
               name:Department of Pharmacology, and the Lineberger Comprehensive Cancer Center, CB #7365 FLOB, University of North Carolina at Chapel Hill, USA
               type:PostalAddress
            type:Organization
      name:Channing J. Der
      affiliation:
            name:University of North Carolina at Chapel Hill
            address:
               name:Department of Pharmacology, and the Lineberger Comprehensive Cancer Center, CB #7365 FLOB, University of North Carolina at Chapel Hill, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Pharmacology, and the Lineberger Comprehensive Cancer Center, CB #7365 FLOB, University of North Carolina at Chapel Hill, USA
      name:Department of Pharmacology, and the Lineberger Comprehensive Cancer Center, CB #7365 FLOB, University of North Carolina at Chapel Hill, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(132)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.21s.

LINK . SPRINGER . COM {}